Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

With no currently approved options in the adjuvant setting, these landmark results demonstrate Libtayo could represent a major advance in delaying recurrence in these vulnerable patients.” C-POST ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

The C-POST study involved 415 patients ... in the first half of 2025. Libtayo is already established as a standard of care for certain patients with advanced CSCC. However, its potential new ...

LIBTAYO's robust efficacy in high-risk CSCC and potential blockbuster status ... There are presently 11 Phase III studies being explored in a diverse array of disease areas that may be further ...

The C-POST study involved 415 patients who were ... in the first half of 2025. Libtayo is already established as a standard of care for certain patients with advanced CSCC. However, its potential new ...

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery. Adjuvant treatment with cemiplimab (Libtayo ...

Arts & Architecture’s Case Study House program was supposed to be about creating replicable, affordable designs for post-war living—stylish but modest homes for young families on a budget.

CBSE Class 10 Science Chapter Wise Important Case Study Questions: CBSE board exams are about to get started. Well, the Class 10 students are busy finishing their syllabus, revising important ...